Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD – Compass Pathways (NASDAQ:CMPS), ATAI Life Sciences (NASDAQ:ATAI) – Beragampengetahuan
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Public Benefit Corporation has secured over $100 million in a Series A private stock sale. The funds will support the final stages of its application for regulatory approval to sell MDMA, also known as ecstasy, as a treatment […]
